Blog
    Regulatory UpdateFor PhysiciansJuly 6, 2026

    FDA peptide compounding status and GLP-1 safety updates

    Review FDA Category 2 status for BPC-157 and TB-500, plus emerging safety signals for semaglutide including NAION and pulmonary aspiration risk.

    Clinical Question

    What is the current regulatory status of commonly compounded peptides under FDA guidelines, and what emerging safety signals have been identified in the postmarketing surveillance of approved peptide therapies?

    Evidence Snapshot

    • Regulatory Status: Multiple peptides (BPC-157, TB-500, GHK-Cu, CJC-1295, Ipamorelin) classified as FDA Category 2 bulk substances as of March 2026.
    • Warning Letters: Tailor Made Compounding (2020) and Predator Nutrition (Oct 2020) cited for regulatory violations regarding various peptides.
    • Clinical Outcomes (Approved Peptides): Semaglutide Phase III STEP 1 trial demonstrated 14.9% weight loss; SELECT trial showed 20% MACE reduction.
    • Clinical Outcomes (Emerging Peptides): Tirzepatide (SURMOUNT-1) showed 22.5% weight loss; Retatrutide Phase II showed 24.2% weight loss at 12mg.
    • Safety Signals: FAERS data for Semaglutide includes Strong ROR for nausea/vomiting and emerging signals for NAION and pulmonary aspiration.

    What the Research Shows

    Evidence from recent FDA regulatory updates (as of March 2026) indicates a significant shift in the eligibility of various peptides for routine compounding. Peptides such as BPC-157, TB-500, and several growth hormone-releasing peptides (GHRPs) are currently classified under Category 2 bulk substances. This classification is primarily driven by reported immunogenicity concerns and a lack of established safety data for human use. Specifically, BPC-157 was designated as a Category 2 substance in September 2023 due to significant safety risks, rendering it ineligible for routine 503A compounding.

    In the clinical domain, evidence for GLP-1 and dual GIP/GLP-1 receptor agonists shows significant metabolic efficacy. The STEP 1 trial (NCT03548935) confirmed 14.9% weight loss with Semaglutide, while the SELECT trial (NCT03574597) demonstrated a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide demonstrated superiority in weight loss in the SURMOUNT-5 trial (NCT05024032) compared to Semaglutide. Retatrutide reaching 24.2% weight loss in Phase II (NCT04881706) is currently undergoing Phase III evaluation in the TRIUMPH-3 trial.

    Conversely, clinical evidence for other peptides has been less definitive. A Phase III trial (NCT02867267) investigating Thymosin Alpha-1 for sepsis reported negative results, showing no reduction in mortality.

    Mechanism

    The provided data does not include specific molecular mechanism of action details for the listed regulatory statuses or clinical trials, beyond identifying class-based safety concerns such as immunogenicity risks for BPC-157, TB-500, GHK-Cu, and GHRP-2, and increased heart rate associated with CJC-1295.

    Limitations of the Evidence

    The regulatory records highlight a general lack of human exposure data for several peptides, most notably TB-500. While Thymosin Alpha-1 is approved as Zadaxin in over 35 countries, it remains not FDA-approved and is currently viewed as a substance of concern under interim FDA policy. Safety signals regarding nonarteritic anterior ischemic optic neuropathy (NAION) for Semaglutide are grounded in an emerging signal of 96 cases through December 2024 but await formal conclusion from the EMA review initiated in January 2025. Similarly, while suicidal ideation is listed in the Semaglutide label (Section 5.9), current data do not support a higher risk compared to background rates.

    Clinical Takeaway

    Clinicians should note that BPC-157, TB-500, GHK-Cu, CJC-1295, and Ipamorelin are currently restricted by the FDA as Category 2 bulk substances due to safety and immunogenicity concerns. For approved agents like Semaglutide, postmarketing surveillance has identified emerging safety signals including pulmonary aspiration risk and NAION, alongside established gastrointestinal adverse effects. All regulatory and safety information is as of March 2026.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Sources

    • FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2; March 2026).
    • FAERS Safety Signal Database (Semaglutide AE Reports through 2023; EMA Review Jan 2025).
    • Clinical Trial Records (STEP 1: PMID 33567185; SELECT: PMID 37952131; SURMOUNT-1: PMID 35658024; Retatrutide Ph II: PMID 37351564; TESTS: PMID 39814420).

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1retatrutide

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.